Aiforia - Medical Image Analysis Software

Here is an equity research report on Aiforia after H1 from Antti :slight_smile:

Aiforia’s early-year revenue development was already known following the July profit warning. Profitability in H1 fell short of our expectations due to higher-than-anticipated operating expenses and a one-off personnel cost. Customer wins accumulated during the period, but their conversion into revenue is progressing slowly. We reiterate our Reduce recommendation and lower our target price to EUR 1.1 (previously EUR 1.3) in line with our lowered forecasts. We consider the risk-reward ratio to remain unsatisfactory due to growth uncertainty and ongoing losses.

5 Likes